메뉴 건너뛰기
Japanese Journal of Cancer and Chemotherapy
Volumn 37, Issue 7, 2010, Pages 1259-1264
Effective therapeutic regimens for patients with triple-negative (ER/PgR/HER2-negative) metastatic breast cancer
Author keywords

Metastatic breast cancer; Triple negative
Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; CISPLATIN; DOXIFLURIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; METHOTREXATE; NAVELBINE; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE;
EID: 79961113110     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (4)
References (7)
  • 1
    • 55849132481 scopus 로고    scopus 로고
    • Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: High incidence of central nervous system metastases
    • Lin NU, Claus EC, Sohl J, et al: Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: High incidence of central nervous system metastases. Cancer 113: 2638-2645, 2008.
    • (2008) Cancer , vol.113 , pp. 2638-2645
    • Lin, N.U.1    Claus, E.C.2    Sohl, J.3
  • 2
    • 42949148257 scopus 로고    scopus 로고
    • Phase II study of Sunitinib Malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
    • Burstein HJ, Elias AD, Rugo HS, et al: Phase II study of Sunitinib Malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26: 1810-1816, 2008.
    • (2008) J Clin Oncol , vol.26 , pp. 1810-1816
    • Burstein, H.J.1    Elias, A.D.2    Rugo, H.S.3
  • 3
    • 68449096428 scopus 로고    scopus 로고
    • Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial
    • abstr 3
    • O'shaughnessy J, Osborne C, Pippen J, et al: Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial. J Clin Oncol 27(suppl): abstr 3, 2009.
    • (2009) J Clin Oncol , vol.27 , Issue.SUPPL.
    • O'Shaughnessy, J.1    Osborne, C.2    Pippen, J.3
  • 4
    • 84958709117 scopus 로고    scopus 로고
    • Japanese source
  • 5
    • 0001369603 scopus 로고    scopus 로고
    • MFL-P chemotherapy for pretreated metastatic breast cancer patients: A regimen with triple biochemical modulation by MTX-5FU, LV-5FU and 5FU-CDDP
    • Kan N and Honda G: MFL-P chemotherapy for pretreated metastatic breast cancer patients: A regimen with triple biochemical modulation by MTX-5FU, LV-5FU and 5FU-CDDP. Breast Cancer 6: 187-191, 1999.
    • (1999) Breast Cancer , vol.6 , pp. 187-191
    • Kan, N.1    Honda, G.2
  • 6
    • 84958709118 scopus 로고    scopus 로고
    • Japanese source
  • 7
    • 2942615257 scopus 로고    scopus 로고
    • The anti-angiogenic basis of metronomic chemotherapy
    • Kerbel RS and Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nature Reviews Cancer 4: 423-436, 2004.
    • (2004) Nature Reviews Cancer , vol.4 , pp. 423-436
    • Kerbel, R.S.1    Kamen, B.A.2

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.